Use of chlorogenic acid in the preparation of a drug for preventing or treating adverse pregnancy outcomes
Intervention with chicoric acid (LCA) in pregnant patients with overactive IFN-I signaling resolved adverse pregnancy outcomes caused by overactive IFN-I signaling, improved embryo survival and offspring health, and showed significant effects, particularly in pregnancies with systemic lupus erythematosus.
Patent Information
- Application Number
- CN202510050715.6
- Authority / Receiving Office
- CN · China
- Patent Type
- Patents(China)
- Current Assignee / Owner
- Filing Date
- 2025-01-13
- Publication Date
- 2025-12-09
- Estimated Expiration
- 2045-01-13
AI Technical Summary
Existing technologies cannot effectively address adverse pregnancy outcomes caused by excessive activation of IFN-I signaling, especially in pregnancies with autoimmune diseases such as systemic lupus erythematosus, leading to problems such as abnormal embryo resorption and development.
Using chicoric acid (especially LCA) as a drug component, intraperitoneal injection can be used to intervene in pregnant patients with excessive activation of IFN-I signaling, and to prevent and treat adverse pregnancy outcomes such as spontaneous abortion, intrauterine growth restriction, and premature birth.
Chicoric acid significantly improved embryo survival and offspring health, and reduced the occurrence of adverse pregnancy outcomes, especially in SLE pregnancy models with excessive IFN-I signaling, demonstrating high safety and efficacy.